Chris Pak

Company: Molecular Targeting Technologies

Job title: President

Seminars:

Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential 9:00 am

This workshop will focus on assessing the commercial and pharmaceutical viability of new isotopes in radiopharmaceutical production. Participants will explore the challenges and strategies for bringing isotopes actinium-225, lutetium-177, lead-212 and copper-67 to market. This workshop will cover: Assessing Market Demand and Commercial Viability: Examine the market demand for new isotopes by analyzing therapeutic potential,…Read more

day: Pre-Conference Workshop Day

Reducing Isotope Demand With an Innovative TRP Delivery Platform 12:45 pm

Common challenges of short-lived, rapidly clearing TRP. Strategies to overcome these challenges while maintaining product integrity and compliance with regulatory standards Evans Blue modification significantly improves pharmacokinetics of targeted peptide radiotherapeutics reducing required dose by >50% Lowering isotope use while maintaining efficacy and safety, improves costs, logistics and health economics, potentially expanding the marketRead more

day: Conference Day One